Exchange: NASDAQ·Updated 07:37 PM EDT
News
all
press releases
Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer PR Newswire SOUTH SAN...
PR Newswire
More News
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rigel Reports Second Quarter 2026 Financial Results
Rigel Reports Second Quarter 2026 Financial Results Rigel Reports Second Quarter 2026 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations...
PR Newswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., July 28, 2026 SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire...
PR Newswire
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., July 7, 2026 SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire...
PR Newswire
Rigel CMO Lisa Rojkjaer Retires, Alison Hannah Appointed As New CMO
(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) announced that Lisa Rojkjaer retired as Chief Medical Officer of the company on July 1, 2026, and Alison Hannah was appointed as the new CMO the same day...
Nasdaq News: Markets
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif., July 1, 2026 Dr. Hannah has decades of oncology drug development experience and has served on Rigel's...
PR Newswire
Rigel Announces Closing of Licensing Agreement for VEPPANU (vepdegestrant)
Rigel Announces Closing of Licensing Agreement for VEPPANU (vepdegestrant) Rigel Announces Closing of Licensing Agreement for VEPPANU (vepdegestrant) PR Newswire SOUTH SAN FRANCISCO, Calif., June 16, 2026 SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.(Nasdaq...
PR Newswire
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel to Present at the Jefferies Global Healthcare Conference Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., May 27, 2026 SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial...
PR Newswire

Advertisement|Remove ads.